Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2

J Neurosurg. 2014 Dec:121 Suppl:143-9. doi: 10.3171/2014.8.GKS141503.

Abstract

Object: The aim of this study was to evaluate long-term clinical outcomes after Gamma Knife surgery (GKS) for patients with neurofibromatosis Type 2 (NF2) and the role of GKS in the management of NF2.

Methods: From December 1994 through December 2008, a total of 46 patients (21 male, 25 female) with NF2 underwent GKS and follow-up evaluation for at least 5 years at the Gamma Knife Center of the Beijing Neurosurgical Institute. GKS was performed using the Leksell Gamma Knife Models B and C. The mean age of the patients was 30 years (range 13-59 years). A family history of NF2 was found for 9 (20%) patients. The NF2 phenotype was thought to be Wishart for 20 (44%) and Feiling-Gardner for 26 (56%) patients. Among these 46 patients, GKS was performed to treat 195 tumors (73 vestibular schwannomas and 122 other tumors including other schwannomas and meningiomas). For vestibular schwannomas, the mean volume was 5.1 cm(3) (median 3.6 cm(3), range 0.3-27.3 cm(3)), the mean margin dose was 12.9 Gy (range 10-14 Gy), and the mean maximum dose was 27.3 Gy (range 16.2-40 Gy). For other tumors, the mean volume was 1.7 cm(3) (range 0.3-5.5 cm(3)), the mean margin dose was 13.3 Gy (range 11-14 Gy), and the mean maximum dose was 26.0 Gy (range 18.0-30.4 Gy). The median duration of follow-up was 109 months (range 8-195 months).

Results: For the 73 vestibular schwannomas that underwent GKS, the latest follow-up MR images demonstrated regression of 30 (41%) tumors, stable size for 31 (43%) tumors, and enlargement of 12 (16%) tumors. The total rate of tumor control for bilateral vestibular schwannomas in patients with NF2 was 84%. Of the 122 other types of tumors that underwent GKS, 103 (85%) showed no tumor enlargement. The rate of serviceable hearing preservation after GKS was 31.9% (15/47). The actuarial rates for hearing preservation at 3 years, 5 years, 10 years, and 15 years were 98%, 93%, 44%, and 17%, respectively. Of the 46 patients, 22 (48%) became completely bilaterally deaf, 17 (37%) retained unilateral serviceable hearing, and 7 (15%) retained bilateral serviceable hearing. The mean history of the disease course was 12 years (range 5-38 years).

Conclusions: GKS was confirmed to provide long-term local tumor control for small- to medium-sized vestibular schwannomas and other types of tumors, although vestibular schwannomas in patients with NF2 responded less well than did unilateral sporadic vestibular schwannomas. Phenotype is the most strongly predictive factor of final outcome after GKS for patients with NF2. The risk for loss of hearing is high, whereas the risk for other cranial nerve complications is low.

Keywords: GKS = Gamma Knife surgery; Gamma Knife surgery; NF2 = neurofibromatosis type 2; long-term follow-up studies; neurofibromatosis Type 2; stereotactic radiosurgery.

MeSH terms

  • Adolescent
  • Adult
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Hearing
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Meningeal Neoplasms / mortality
  • Meningeal Neoplasms / surgery*
  • Meningioma / mortality
  • Meningioma / surgery*
  • Middle Aged
  • Neurofibromatosis 2 / mortality
  • Neurofibromatosis 2 / surgery*
  • Neuroma, Acoustic / mortality
  • Neuroma, Acoustic / surgery*
  • Radiosurgery / methods*
  • Time Factors
  • Treatment Outcome
  • Young Adult